Kenneth Kastaniegaard, CEO of Biogenity, commented:
"TAmiRNA is a well-established player in the field of transcriptomics, with a focus on using microRNA (miRNA) as diagnostic and therapeutic targets. Combining this data with proteomics can bring essential insight into molecular signals and the biological response they cause."
MicroRNAs are small non-coding RNAs that play a critical role in regulating gene expression and are often involved in the development of diseases such as cancer.
The collaboration will allow Biogenity to leverage TAmiRNA's state-of-the-art transcriptomics technologies, including Next-Generation Sequencing (NGS) and bioinformatics analysis tools. NGS is a powerful technology that enables researchers to sequence large amounts of DNA or RNA in a short amount of time, making it possible to study the transcriptome of thousands of cells at once.
The new availability of transcriptomics technologies allows Biogenity to expand its expertise in the field of transcriptomics, which resonates with Biogenity's aim of enabling more Multi-omics driven studies. Multi-omics shows excellent potential for the development of personalized medicine and system biology. Biogenity's advanced bioinformatics integrates the two disciplines paving the way for innovations and knowledge.
Completeness and transparency are also one of the reasons for the partnership. Together, Biogenity and TAmiRNA are now able to offer their clients complete omics workflows for multiomics under one contract. Not only ensuring the same high standard but also that the study design is favorable towards combining data.
In conclusion, the collaboration between Biogenity and TAmiRNA is a big step towards further enabling our clients to identify new biomarkers that can be used to diagnose disease, monitor treatment response, and predict patient outcomes. And an important step in Biogenity's vision is to advance omics research and bring better healthcare to future generations.